arXiv:2605.27561v1 Announce Type: new Abstract: Introduction. Early detection of malignant skin lesions is critical for prognosis, yet dermatologist shortages in Russian regions limit screening coverage. Mobile dermoscopy clinical decision support systems (CDSS) offer a promising approach, with model interpretability and standardised patient routing remaining key barriers to adoption. Aim. To develop a quantitative interpretability assessment method for cascade deep learning models and a three-zone patient routing algorithm, and to conduct a preliminary single-centre prospective clinical validation of the Melanoscope AI CDSS in Russian outpatient practice. Material and methods. Two-stage cascade classification of dermoscopic images; attention map visualisation (attention rollout for ViT and Swin; Grad-CAM for ConvNeXt and EfficientNetV2); quantitative IoU-based agreement assessment between activation maps and expert annotations; prospective single-centre validation across four "Melanoma Day" sessions (Orel, Russia, June 2025 - April 2026). Results. On 176 patients: agreement with expert assessment 88.6%; no false negatives among 5 malignant lesions (95% CI: 47.8-100.0%); specificity 88.3%. Three melanomas and two basal cell carcinomas were histologically confirmed; six dysplastic naevi placed under follow-up. Mean IoU (n=180): ViT - 0.69; Swin - 0.64; ConvNeXt - 0.53; EfficientNetV2 - 0.51. Routing thresholds: P<0.15 / 0.15-0.50 / >=0.50. Conclusion. No false negatives were observed; specificity was 88.3%, supporting screening use. The integrated cascade classification, attention map visualisation with IoU assessment, and three-zone routing provide reproducible, interpretable clinical decision support adaptable to varying resource levels.
Clinical Validation of the Melanoscope AI Mobile Dermoscopy Clinical Decision Support System
A preliminary clinical validation of the Melanoscope AI mobile dermoscopy clinical decision support system, conducted across four "Melanoma Day" screening sessions in Orel, Russia from June 2025 to April 2026, found no false negatives among five malignant lesions and achieved 88.3% specificity in 176 patients. The system, which uses cascade deep learning models with attention map visualization and a three-zone patient routing algorithm, demonstrated 88.6% agreement with expert assessment and histologically confirmed three melanomas and two basal cell carcinomas. The results support the system's potential for screening use in Russian outpatient practice, where dermatologist shortages limit skin cancer detection coverage.
Run your AI side-project on zahid.host
EU-based hosting, git-push deploys, automatic HTTPS, no cold starts. Free tier with a custom domain — perfect for shipping the agent you just read about.